GlycoMimetics, Inc. (NASDAQ:GLYC) Files An 8-K Regulation FD Disclosure

GlycoMimetics, Inc. (NASDAQ:GLYC) Files An 8-K Regulation FD Disclosure
Item 7.01    Regulation FD Disclosure.

Story continues below

On November 21, 2019, GlycoMimetics, Inc. (the “Company”) presented a company overview at the Jefferies 2019 London Healthcare Conference. As part of this presentation, the Company updated its guidance regarding the Company’s Phase 3 clinical trial of uproleselan in relapsed/refractory AML, stating that it now expects top-line results in 2021.

 The information in this Item 7.01 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

2

About GlycoMimetics, Inc. (NASDAQ:GLYC)

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

An ad to help with our costs